8 November 2022
Bioventix plc
("Bioventix” or the "Company")
Posting of Annual
Report and Notice of AGM
Bioventix plc (AIM: BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, announces that
it has today posted its Annual Report for the year ended
30 June 2022 together with a Notice
of Annual General Meeting ("AGM") and Form of Proxy to shareholders
that have elected to receive documentation in hard copy format.
Both documents will also be available from the Company's website at
www.bioventix.com under the Investors section.
The Company's AGM will be held at Farnham Castle, Farnham,
Surrey, GU9 0AG on Thursday 8 December
2022 at 2.00pm.
For further information please contact:
Bioventix plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.
